Module

Strategies for Further Enhancing Outcomes in Patients With Virologic Suppression

Source: An Eye on the Future: Planning for Long-term Antiretroviral Success

Strategies for Further Enhancing Outcomes in Patients With Virologic Suppression

Program Director: W. David Hardy, MD

Faculty:

Edwin DeJesus, MD, FACP, AAHIVS

CREDIT INFORMATION

Release Date: February 12, 2009

Expiration Date: February 11, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount practice guideline recommendations regarding treatment simplification strategies for virologically suppressed patients
Discuss the results of clinical trials of virologically suppressed patients who switched single agents within the same classes
Describe the results of clinical trials of virologically suppressed patients who had treatment simplified to coformulated agents

Topics covered include:

Introduction
Considerations When Modifying Antiretroviral Therapy Regimens
Definition and Examples of Antiretroviral Simplification Switch Strategies
Simplification Switch Studies to Coformulated Antiretroviral Drugs
Switch Strategies Using Agents Within the Same Drug Class
Switch Strategies Using Agents From Other Classes
Preventing Drug-Related Adverse Events Through a Preemptive Switch Strategy
Conclusion

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.